Our retrospective on the availability of genetic support for all FDA approvals during the last decade is now available in @NatRevDrugDisc 🧵 bit.ly/3Q5WIvo
Last year, we reported two-thirds of 2021 approved drugs presented genetic evidence between the intended pharmacological target and the indication go.nature.com/46ExIAY
Apr 28, 2022 • 6 tweets • 5 min read
Big leap for the @OpenTargets platform. Gene burden from 450k+ @uk_biobank exomes from @AstraZeneca and @Regeneron, ClinVar structural variants, NLP classification of clinical trials stop reasons and drug label indications,etc. Systematically filling the gaps one-by-one 🧵
On our mission to identify potential causal targets from genetics 🧬, the strongly-powered @uk_biobank burden tests provide us an opportunity to close the gap between rare disease variation, and common variation from GWAS studies - as post-processed by the Genetics Portal
Aug 12, 2021 • 5 tweets • 4 min read
Systematically overlaying likely pathogenic variants over @DeepMind#AlphaFold predicted structures provides a unique opportunity to dive into the mechanisms of disease.
Here, NOD2 inflammatory disease-causing variants on the experimentally unresolved structure. 1/5
